Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2025 | Assessing the long-term role of enzalutamide for mHSPC

Andrew Armstrong • 1 Jun 2025

ASCO 2025

ARCHES

Andrew Armstrong, MD, MS, Duke Cancer Institute, Durham, NC, discusses the changes in the treatment landscape for metastatic hormone-sensitive prostate cancer (mHSPC) since the ARCHES trial (NCT02677896) was first designed. ARCHES demonstrated a five-year survival improvement with the androgen receptor pathway inhibitor (ARPI) enzalutamide, delaying post-progression therapies – an insight that still informs modern therapies despite the availability of newer treatment options. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.